Tango Therapeutics, Inc. (TNGX)
| Market Cap | 3.63B |
| Revenue (ttm) | 62.38M |
| Net Income (ttm) | -101.59M |
| Shares Out | 144.24M |
| EPS (ttm) | -0.87 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,864,778 |
| Open | 25.84 |
| Previous Close | 26.33 |
| Day's Range | 24.24 - 26.43 |
| 52-Week Range | 1.03 - 28.41 |
| Beta | 1.32 |
| Analysts | Strong Buy |
| Price Target | 21.78 (-13.37%) |
| Earnings Date | May 8, 2026 |
About TNGX
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to ... [Read more]
Financial Performance
In 2025, Tango Therapeutics's revenue was $62.38 million, an increase of 48.29% compared to the previous year's $42.07 million. Losses were -$101.59 million, -22.03% less than in 2024.
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for TNGX stock is "Strong Buy." The 12-month stock price target is $21.78, which is a decrease of -13.37% from the latest price.
News
Tango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of Vopimetostat
- Matthew Gall appointed Chief Financial Officer - - Additional key appointments add expertise in clinical operations, corporate strategy and project leadership -
Tango Therapeutics Transcript: Leerink Global Healthcare Conference 2026
The session highlighted progress in PRMT5 inhibitor development, with vopimetostat showing promising efficacy and safety in pancreatic cancer and ongoing combination trials with RAS inhibitors. New collaborations and a brain-penetrant compound expand the pipeline, aiming to transform treatment options.
Tango Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference
Vopimetostat, a selective PRMT5 inhibitor, is advancing through pivotal trials in pancreatic and lung cancers, with strong early efficacy and safety data. Combination studies with RAS inhibitors and new CNS-penetrant candidates are progressing, supported by robust financials.
Tango Therapeutics Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026
Leadership transition brings continuity, with a focus on advancing vopimetostat toward regulatory approval. Key trials in pancreatic and lung cancer are progressing, with pivotal and combination data expected this year. Pipeline expansion includes TNG456 and TNG961, targeting new indications.
Tango Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference
Leadership transitioned to Malte Peters, ensuring continuity as the company advances late-stage clinical development for MTAP-deleted cancers. Key milestones include pivotal trials in pancreatic cancer, combination studies with RAS inhibitors, and expansion into glioblastoma, supported by strong financials and FDA-aligned strategies.
Tango Therapeutics Announces CEO Transition: Barbara Weber to Retire, Malte Peters Appointed Successor
BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cance...
Tango Therapeutics Appoints Sung Lee to Board of Directors
BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cance...
Tango Therapeutics to Participate in 44th Annual J.P. Morgan Healthcare Conference
BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled t...
Tango Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference
Three clinical programs are advancing, with Vopimetostat showing strong efficacy in pancreatic cancer and a pivotal phase III set for 2026. FDA-aligned trial design, competitive differentiation, and a cash runway into 2028 support execution of key milestones.
Tango Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference
BOSTON, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that Adam Crystal, M.D., Ph.D., President of Research & Development at Tango Therapeutics, is schedul...
Tango Therapeutics Transcript: Jefferies London Healthcare Conference 2025
Vopimetostat shows promising efficacy in MTAP-deleted cancers, with a pivotal second-line pancreatic cancer study design agreed upon by the FDA. Combination studies with RAS inhibitors are progressing rapidly, with key data updates expected next year. Cash runway extends into 2028.
Tango Therapeutics Touts Encouraging Data From Early-Stage Cancer Trial, Raises Capital To Fund Advancement
Tango Therapeutics Inc. (NASDAQ:TNGX) revealed data from its ongoing Phase 1/2 study of vopimetostat (TNG462) in patients with MTAP-deleted cancers.
Tango Therapeutics Transcript: Study Update
Vopimetostat, a selective PRMT5 inhibitor, showed a 27% overall response rate and strong safety in MTAP-deleted cancers, with particularly promising results in second-line pancreatic and histology-agnostic cohorts. A pivotal phase III trial is planned for 2026, supported by new financing and ongoing combination studies.
Tango Therapeutics Announces $225 Million Financing
Financing participants include Farallon Capital Management, TCGX, Balyasny Asset Management, Woodline Partners LP, Nextech, Invus, Adage Capital Management LP, Boxer Capital Management, Logos Capital,...
Tango Therapeutics to Present First Clinical Data from TNG260 at Society for Immunotherapy of Cancer (SITC) Annual Meeting 2025
BOSTON, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cance...
Tango Therapeutics Transcript: Cantor Global Healthcare Conference 2025
TNG462, a selective PRMT5 inhibitor, is showing promising efficacy and tolerability in MTAP-deleted cancers, with pivotal pancreatic cancer data expected in the second half of the year. Combination trials with RAS inhibitors are underway, and a brain-penetrant PRMT5 inhibitor is advancing for glioblastoma.
Tango Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference
BOSTON, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled t...
Tango Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights
– First patient dosed in combination trial of TNG462 and Revolution Medicines RAS(ON) inhibitors – – First patient dosed in Phase 1/2 trial with TNG456, a brain-penetrant MTA-cooperative PRMT5 inhibit...
Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG462 plus Revolution Medicines' Daraxonrasib or Zoldonrasib in Patients with RAS-Mutant MTAP-deleted Pancreatic or Lung Cancer
BOSTON, June 27, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering the next generation of precision cancer medicines, to...
Tango Therapeutics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference
The session highlighted advances in synthetic lethality, with TNG462 and TNG456 advancing in MTAP-deleted cancers and glioblastoma, respectively. Durable responses, strong tolerability, and a focus on RAS-mutant combinations position the pipeline for pivotal studies and competitive leadership.
Tango Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference
BOSTON, May 27, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to...
Tango Therapeutics Announces First Patient Dosed in TNG456 Phase 1/2 Trial in Patients With MTAP-deleted Glioblastomas and Other Solid Tumors
BOSTON, May 21, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering the next generation of precision cancer medicines, tod...
Tango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights
– Data update from ongoing TNG462 Phase 1/2 monotherapy trial expected 2H 2025 – – Combination trial of TNG462 + Revolution Medicines RAS(ON) inhibitors on track for enrollment 2Q 2025 – – Cash positi...
Tango Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025
BOSTON, May 01, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that it will report first quarter 2025 financial results on May 12, 2025, before the open of the U.S. ...
Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline with Five Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025
BOSTON, March 25, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision canc...